Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

MEK and RAF inhibitors for BRAF-mutated cancers.

Belden S, Flaherty KT. MEK and RAF inhibitors for BRAF-mutated cancers. Expert Rev Mol Med. 2012 Oct 12; 14:e17.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.